Varsha Gandhi
Affiliations: | The University of Texas Graduate School of Biomedical Sciences at Houston |
Area:
Biochemistry, Pharmacology, Oncology, Cell BiologyGoogle:
"Varsha Gandhi"Mean distance: (not calculated yet)
Children
Sign in to add trainee
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Tantawy SI, Timofeeva N, Sarkar A, et al. (2023) Targeting MCL-1 protein to treat cancer: opportunities and challenges. Frontiers in Oncology. 13: 1226289 |
| Timofeeva N, Ayres ML, Baran N, et al. (2023) Preclinical investigations of the efficacy of the glutaminase inhibitor CB-839 alone and in combinations in chronic lymphocytic leukemia. Frontiers in Oncology. 13: 1161254 |
| Aslan B, Kismali G, Iles LR, et al. (2022) Pirtobrutinib inhibits wild-type and mutant Bruton's tyrosine kinase-mediated signaling in chronic lymphocytic leukemia. Blood Cancer Journal. 12: 80 |
| Yi X, Jain N, Iles LR, et al. (2022) Targeting Mcl-1 by AMG-176 During Ibrutinib and Venetoclax Therapy in Chronic Lymphocytic Leukemia. Frontiers in Oncology. 12: 833714 |
| Galan-Cobo A, Stellrecht CM, Yilmaz E, et al. (2021) Enhanced vulnerability of LKB1-deficient NSCLC to disruption of ATP pools and redox homeostasis by 8-Cl-Ado. Molecular Cancer Research : McR |
| Aslan B, Kismali G, Chen LS, et al. (2021) Development and characterization of prototypes for in vitro and in vivo mouse models of ibrutinib-resistant CLL. Blood Advances. 5: 3134-3146 |
| Timofeeva N, Gandhi V. (2021) Ibrutinib combinations in CLL therapy: scientific rationale and clinical results. Blood Cancer Journal. 11: 79 |
| Buettner R, Nguyen LXT, Morales C, et al. (2021) Targeting the metabolic vulnerability of acute myeloid leukemia blasts with a combination of venetoclax and 8-chloro-adenosine. Journal of Hematology & Oncology. 14: 70 |
| Bose P, Gandhi V. (2021) Managing chronic lymphocytic leukemia in 2020: an update on recent clinical advances with a focus on BTK and BCL-2 inhibitors. Faculty Reviews. 10: 22 |
| Sarkar A, Stellrecht CM, Vangapandu HV, et al. (2020) Ataxia telangiectasia mutated interacts with Parkin and induces mitophagy independent of kinase activity. Evidence from mantle cell lymphoma. Haematologica |